Cepheid's Xpert Flu/RSV Test Gets CE Mark | GenomeWeb

NEW YORK (GenomeWeb News) — Cepheid said today that it has received CE marking for Xpert Flu/RSV XC, an on-demand molecular test for determination of influenza A and B infection and differentiation of respiratory syncytial virus infection.

The new test runs on Cepheid's GeneXpert system, of which more than 7,000 are installed worldwide, Cepheid said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.